Previous 10 | Next 10 |
home / stock / pali / pali articles
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded up 0.13% to 37,784.21 whi...
Palisade Bio, Inc. (NASDAQ:PALI) shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bi...
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the ...
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 ...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday. The Dow traded down 0.04% to 38,093....
Palisade Bio Inc (NASDAQ:PALI) shares are trading higher after the company announced the presentation of preclinical data of its lead asset, P...
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 25 points on Monday. Following the market opening Monday, ...
ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares rose sharply in today's pre-market trading after Jefferies upgraded the stock from Hol...
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This...
News, Short Squeeze, Breakout and More Instantly...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy dev...
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisad...